In what ways does tigecycline's metabolism influence its dosing frequency?

How does tigecycline's metabolism shape its dosing schedule?
Tigecycline undergoes minimal hepatic metabolism and is eliminated primarily through biliary excretion and feces, with only about 10–15% recovered in urine as unchanged drug. Because these routes do not produce active metabolites that accumulate, standard regimens rely on a loading dose of 100 mg followed by 50 mg every 12 hours to maintain steady-state concentrations without the need for more frequent dosing.

Why is twice-daily dosing required despite slow elimination?
The drug’s large volume of distribution (7–10 L/kg) and extensive tissue penetration cause rapid initial decline in plasma levels, so the 12-hour interval keeps trough concentrations above the MIC for most susceptible pathogens. Less frequent administration would allow plasma levels to fall below the efficacy threshold between doses.

What changes when renal or hepatic function is impaired?
Mild-to-moderate renal impairment does not alter tigecycline clearance enough to require dose adjustment, because renal excretion is a minor pathway. Severe hepatic impairment, however, reduces clearance by roughly 50%, prompting a lower maintenance dose of 25 mg every 12 hours to avoid excessive exposure while still preserving the twice-daily schedule.

Can the dosing interval be extended in any clinical settings?
No formal studies support once-daily regimens, and pharmacokinetic modeling shows that extending the interval beyond 12 hours risks sub-therapeutic concentrations for organisms with higher MICs. Extended-infusion or once-daily strategies remain investigational and are not endorsed by current labeling.

How do drug interactions affect the need for dose or frequency changes?
Potent inducers or inhibitors of hepatic enzymes have little impact on tigecycline exposure because the drug is not metabolized through CYP450 pathways. Consequently, dosing frequency stays constant even when co-administered with most interacting agents.

When does the patent for tigecycline expire and what does that mean for dosing guidance?
The composition-of-matter patent for tigecycline expired in 2015 in the United States, allowing generic versions to enter the market. Approved generic labeling continues to recommend the same 100 mg loading dose followed by 50 mg every 12 hours, reflecting unchanged pharmacokinetic data.